Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Catalyst Pharmaceuticals, Inc. (CPRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
14.10+0.26 (+1.88%)
At close: 04:00PM EDT
13.33 -0.77 (-5.46%)
After hours: 07:59PM EDT
Advertisement

Catalyst Pharmaceuticals, Inc.

355 Alhambra Circle
Suite 801
Coral Gables, FL 33134
United States
305 420 3200
https://www.catalystpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees76

Key Executives

NameTitlePayExercisedYear Born
Mr. Patrick J. McEnanyCo-Founder, Chairman, Pres & CEO1.05MN/A1947
Ms. Alicia Grande C.M.A., CPA, CMA, CPAChief Accounting Officer, VP, Treasurer & CFO617.94kN/A1971
Dr. Steven R. MillerCOO & Chief Scientific Officer745.71kN/A1962
Dr. Gary Ingenito M.D., Ph.D.Chief Medical & Regulatory Officer706.86kN/A1956
Dr. Preethi Sundaram Ph.D.Chief Strategy Officer511.25kN/A1976
Ms. Mary ColemanVP & Head of Investor RelationsN/AN/AN/A
Mr. Brian Elsbernd J.D.Chief Compliance Officer & Chief Legal OfficerN/AN/A1964
Mr. Pete Curry Sr.VP of SalesN/AN/AN/A
Mr. Jeffrey Del CarmenChief Commercial OfficerN/AN/A1971
Mr. Philip B. SchwartzCorp. Sec.N/AN/A1955
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Corporate Governance

Catalyst Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 6. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 5; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement